🤖🔬NIH #AI tool predicts #cancer patients’ #immunotherapy outcomes. The model's efficacy was validated using data from 2,881 patients with 18 different types of solid tumours ⬇️ Vi Pharma Technology Focus pharmaceutical-technology.com/news/nih-ai-to…

🇺🇸🔬 #ASCO2024 | A few takeaways from the ASCO Annual Meeting on lung cancer, breast cancer, hepatocellular carcinoma, and melanoma. This confirms high unmet needs where XENOTHERA’s XON7 could bring strong benefits. 👉 More details in our press release: xenothera.com/2024/06/12/xen…

🫁 #LungCancer #Treatment | Researchers at Brigham and Women's Hospital have developed a cutting-edge nanomedicine therapy that enhances the immune system's ability to target lung cancer cells. Via News Medical ⬇️ medicalxpress.com/news/2024-06-n…

🫀🫁 #Transplantation | Researchers at the Westmead Institute for Medical Research and the University of Sydney have identified universal molecular biomarkers for transplant rejection across all major organs using AI 👇 Medical Xpress medicalxpress.com/news/2024-06-m…

🧬 #Antibodies Market | A recent report by Research and Markets forecasts significant growth in the global research antibodies market, projecting it to reach $6.65 billion by 2029 👇 globenewswire.com/news-release/2…

🔬#CancerResearch | City of Hope's recent study published in Nature Medicine highlights that CBM588, a live biotherapeutic product, can improve outcomes for metastatic kidney cancer patients when combined with #immunotherapy and tyrosine kinase inhibitors. news-medical.net/news/20240628/…

🔬 #LiverCancer | Recent #immunotherapy advancements offer hope for hepatocellular carcinoma (#HCC) patients. Ongoing research aims to refine these treatments and improve patient outcomes 👇 News Medical news-medical.net/news/20240702/…

🦠🔬 #Covid #Traitement | Publication de l’efficacité clinique de notre anticorps anti-COVID, le XAV-19, dans Frontiers in Immunology : pubmed.ncbi.nlm.nih.gov/38694503/ 🔍 Plus d’informations dans notre communiqué : izsogood.co/so/8dP2ICvZI?l…

🦠🔬 #Covid #Treatment | Clinical efficacy of our anti-COVID antibody, XAV-19, published in Frontiers in Immunology : pubmed.ncbi.nlm.nih.gov/38694503/ 🔍 More info in our press release: linkedin.com/feed/update/ur…

🔬 #Cancer #immunotherapy resistance: a recent study published in Science Advances identifies a unique approach to overcoming resistance to cancer immunotherapy. 🔍 Read the full study for more details 🔽 science.org/doi/10.1126/sc… #CancerResearch #Immunotherapy #Oncology

🧬 #PolyclonalAntibodies | This article about GigaGen highlights the incredible potential of polyclonal antibodies in treating various diseases. At XENOTHERA, we are convinced and fully aligned with this innovative approach. Via Drug Target Review 👇 drugtargetreview.com/article/151507…

🔬 #Immunotherapy | This insightful article by Cancer Research UK explores how tracking the co-evolution of tumors and the immune system can enhance cancer treatments. news.cancerresearchuk.org/2024/07/24/the…

🌐 #XENOSPHERE: ensuring low immunogenicity with our GH-pAb platform 🧬 ➡️ To find out more about our mission and technology, visit our website: xenothera.com #Innovation #Biotech #Healthcare #Immunology #LowImmunogenicity #PolyclonalAntibodies #GHpAb

🔬 #CancerResearch | A recent article published by Cancer Biology & Medicine, led by researchers from Guangdong Pharmaceutical University, explores significant advancements in immune checkpoint inhibitors (ICIs) ⬇️ #Immunotherapy #CancerTreatment news-medical.net/news/20240814/…

📣 #Lymphoma #Treatment | We announce the recruitment of the first patient for our PALT1 trial, aimed at treating Peripheral T-Cell Lymphoma (#PTCL), and its Orphan Drug Designation (ODD) granted by the EMA. 🔍 More details in our press release: linkedin.com/posts/xenother…

📣 #Lymphome #Traitement | Nous annonçons le recrutement du 1er patient pour notre essai PALT1, visant à traiter le lymphome T périphérique (#PTCL), et sa désignation de médicament orphelin (ODD) accordée par l'EMA. 🔍 Plus d'infos dans notre communiqué : izsogood.co/so/69P6Hp8tY?l…